How big is the sterile injectables CDMO market?

The global sterile injectables CDMO market size was estimated at USD 37.82 billion in 2025 and is expected to reach USD 41.56 billion in 2026.

What is the sterile injectables CDMO market growth?

The global sterile injectables CDMO outsourcing market is expected to grow at a compound annual growth rate of 11.19% from 2026 to 2033 to reach USD 87.34 billion by 2033.

Which segment accounted for the largest sterile injectables CDMO market share?

North America dominated the sterile injectables CDMO market with a share of 33.75% in 2025. This is attributable to the establishment of contract manufacturing facilities, the rise in chronic diseases, and advances in biology. The expansion of the contract manufacturing market is driven primarily by the growing focus on biologics and biosimilars, which often require sterile injectable formulations.

Who are the key players in sterile injectables CDMO market?

Some key players operating in the sterile injectables CDMO market include Boehringer Ingelheim GmbH, Baxter BioPharma Solutions, Vetter Pharma, Recipharm AB, Aenova Group, Fresenius Kabi, FAMAR Health Care Services, NextPharma Technologies, Ajinomoto Bio-Pharma Services, PCI Pharma Services, IDT Biologika, Alcami Corporation, Fareva Group, Eurofins CDMO, Siegfried Holding AG

What are the factors driving the sterile injectables CDMO market?

Key factors driving market growth include a growing focus on developing innovative therapeutics, a preference for personalized medicine, a changing regulatory landscape, increasing outsourcing trends, the adoption of one-stop-shop CDMOs, and growing R&D spending, among others.